(02) 9850 4000
GlyTherix
  • Home
  • Company
    • Financial Statements
  • Product Pipeline
  • For Investors
  • News
  • Contact Us
Select Page
High-Yield GMP-Compliant Primary Cell Bank Established for Miltuximab®

High-Yield GMP-Compliant Primary Cell Bank Established for Miltuximab®

by GlyTherix | Jul 21, 2022

Date, July 21 2022: Sydney. GlyTherix is pleased to announce the successful completion of its high-yield GMP-grade stable cell line development program for its proprietary antibody Miltuximab® in partnership with international biologics manufacturer GenScript ProBio...

ENQUIRIES

Address
Suite 2, Ground Floor, 75 Talavera Road, Macquarie Park, NSW 2113, Australia

Phone
Intl: +612 9850 4000
Aust: 02 9850 4000
(Compare your time zone with Sydney here)

Recent Posts

  • GlyTherix and Adcendo Announce Agreement for Development of Antibody Drug Conjugate
  • GlyTherix and The University of Queensland join forces in ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals
  • GlyTherix IP News

RECENT POSTS

  • GlyTherix and Adcendo Announce Agreement for Development of Antibody Drug Conjugate
  • GlyTherix and The University of Queensland join forces in ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals
  • GlyTherix IP News
  • High-Yield GMP-Compliant Primary Cell Bank Established for Miltuximab®

ENQUIRIES

Address
Suite 2, Ground Floor, 75 Talavera Road, Macquarie Park, NSW 2113, Australia

Phone
Intl: +612 9850 4000
Aust: 02 9850 4000
(Compare your time zone with Sydney here)

MORE INFO

FOR SHAREHOLDERS:
Shareholder Communications Options

Would you like to talk with Glytherix about:

  • Investing in us?
  • Partnering with us?
  • Media events?
  • Some feedback?
  • Home
  • News
  • Terms of Use
  • Privacy Policy
  • Contact Us

COPYRIGHT 2022 | GLYTHERIX - ALL RIGHTS RESERVED